June 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountcollections.plos.org
Global Rank
- -
Country Rank
- -
Category Rank
- -
Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
54.59%
Pages per Visit
1.52
Avg Visit Duration
- -
- Company
- - -
- Industry
- - -
Top 10 collections.plos.org Competitors
The Top 10 Sites Like collections.plos.org in June 2026 are ranked by their affinity to collections.plos.org in terms of keyword traffic, audience targeting, and market overlap
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont
- Company
- - -
- Industry
- - -
Global Rank
#89,900
7,166Bounce Rate
30.02%
Pages per Visit
4.12
Avg Visit Duration
00:01:24
Similarity Score
100%Learn how to search peer-reviewed biomedical literature with PubMed.ai. Discover tips for keyword queries, filters, and research-focused search strategies.
- Company
- - -
- Industry
- - -
Global Rank
#463,215
30,935Bounce Rate
39.11%
Pages per Visit
1.73
Avg Visit Duration
00:00:27
Similarity Score
92%MIT Press - Home Page
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
75.82%
Pages per Visit
1.72
Avg Visit Duration
00:00:39
Similarity Score
88%- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
Human Kinetics
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
63.81%
Pages per Visit
2.09
Avg Visit Duration
00:01:44
Similarity Score
85%Nearly 150 years ago, scientists began to imagine how information might flow through the brain based on the shapes of neurons they had seen under the microscopes of the time. With today’s imaging technologies, scientists can zoom in much further, seeing the tiny synapses through which neurons communicate with one another and even the molecules […]
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
71.83%
Pages per Visit
1.58
Avg Visit Duration
00:00:40
Similarity Score
81%- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
43.11%
Pages per Visit
2.54
Avg Visit Duration
00:01:56
Similarity Score
80%- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
46.76%
Pages per Visit
3.33
Avg Visit Duration
00:02:59
Similarity Score
79%- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
64.59%
Pages per Visit
1.95
Avg Visit Duration
00:00:29
Similarity Score
78%Cascade's Rebecca Pearce is developing a thermal model could that unlock the inexhaustible clean energy beneath our feet.
- Company
- - -
- Industry
- - -
Global Rank
#1,412,865
461,609Bounce Rate
50.64%
Pages per Visit
1.46
Avg Visit Duration
00:00:23
Similarity Score
76%collections.plos.org's top 5 competitors in June 2026 are: scienceopen.com, pubmed.ai, mitpress.mit.edu, wires.onlinelibrary.wiley.com, and more.
According to Similarweb data of monthly visits, collections.plos.org’s top competitor in June 2026 is scienceopen.com. collections.plos.org 2nd most similar site is pubmed.ai, and closing off the top 3 is mitpress.mit.edu.
wires.onlinelibrary.wiley.com ranks as the 4th most similar website to collections.plos.org and journals.humankinetics.com ranks fifth in June 2026.
The other five competitors in the top 10 list are mcgovern.mit.edu, cogsci.berkeley.edu, training.nih.gov, pure.psu.edu, and cascadeinstitute.org.